Academic Highlights: New Developments in Addiction Treatment.[CME]
J Clin Psychiatry 2006;67(11):1801-1812
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Click to enlarge page
George F. Koob, Ph.D., began his presentation by identifying the neurobiology of addiction as the conceptual framework necessary to understand the medications developed for substance dependence. From this perspective, addiction may include positive and negative reinforcement as motivation for drug-seeking behavior, which may become exacerbated with the severity of the addiction.1 For example, impulse- control disorders are motivated by positive reinforcement—feeling tension and arousal, completing the impulsive act, receiving immediate gratification, experiencing guilt or reproach, then starting the cycle over..